[[PAGE:1]]

IMPORTANT IDENTIFIED RISKS

For DRUG-A, important risks include interstitial lung disease, QT prolongation, hepatotoxicity, and severe cutaneous adverse reactions.

[[PAGE:2]]

PHARMACOVIGILANCE MEASURES

Healthcare professionals should report suspected adverse reactions per local requirements. ILD symptoms require prompt evaluation and label-concordant management.